Physician profile
Muhammad Malik
NPI 1447284864
$1,996.65
in general payments reported to CMS, 2019-2025
23 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.92 · 2020: $19.65 · 2022: $69.38 · 2023: $838 · 2024: $906 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,888.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,887.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $480.27 | 2022-2024 | Ffrct |
| Novartis Pharmaceuticals Corporation | $303.81 | 2019-2025 | |
| Pfizer INC. | $186.08 | 2023-2025 | |
| Depuy Synthes Sales INC. | $154.96 | 2024-2025 | Vivigen Mis Delivery System, Teligen |
| Recor Medical INC | $122.06 | 2024 | Paradise Renal Denervation System |
| Astrazeneca Pharmaceuticals Lp | $117.05 | 2023-2024 | Farxiga |
| Irhythm Technologies, INC. | $105.46 | 2024 | Zio Xt Patch, Zio Monitor |
| Janssen Pharmaceuticals, INC | $61.78 | 2024 | Xarelto |
| Amgen INC. | $55.72 | 2023-2024 | Repatha |
| Novo Nordisk INC | $44.11 | 2023-2024 | Ozempic, Rybelsus |
| Lexicon Pharmaceuticals, INC. | $42.55 | 2023-2024 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $40.99 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $40.67 | 2023-2024 | Verquvo |
| Lantheus Medical Imaging, INC. | $38.22 | 2023 | Definity |
| Boston Scientific Corporation | $33.59 | 2024 | Watchman Flx |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $32.87 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.26 | 2022-2023 | Jardiance |
| Kiniksa Pharmaceuticals, Ltd. | $21.60 | 2023 | Arcalyst |
| Genzyme Corporation | $20.24 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.94 | 2023 | Lifevest |
| Haemonetics Corporation | $17.60 | 2023 | Teg6s Hemostasis System |
| Philips North America LLC | $15.72 | 2025 | Vest Therapy Und |
| Chiesi USA, INC. | $13.10 | 2024 | Cleviprex, Kengreal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.